Goldman Sachs
BDTX icon

Goldman Sachs’s Black Diamond Therapeutics BDTX Stock Holding History

Goldman Sachs’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.46M Buy
684,418
+359,091
+110% +$854K ﹤0.01% 4806
2025
Q4 		$791K Sell
325,327
-123,691
-28% -$438K ﹤0.01% 5295
2025
Q3 		$1.7M Buy
449,018
+98,374
+28% +$288K ﹤0.01% 4616
2025
Q2 		$870K Sell
350,644
-128,743
-27% -$248K ﹤0.01% 4801
2025
Q1 		$743K Sell
479,387
-4,449
-0.9% -$9.33K ﹤0.01% 4921
2024
Q4 		$1.04M Buy
483,836
+202,820
+72% +$581K ﹤0.01% 4802
2024
Q3 		$1.22M Buy
281,016
+217,896
+345% +$1.19M ﹤0.01% 4503
2024
Q2 		$294K Sell
63,120
-270,128
-81% -$1.45M ﹤0.01% 5117
2024
Q1 		$1.69M Buy
333,248
+287,263
+625% +$1.16M ﹤0.01% 3983
2023
Q4 		$129K Buy
+45,985
New +$108K ﹤0.01% 5251
2023
Q2 		– Sell
-36,679
Closed -$69.3K – 5753
2023
Q1 		$69.3K Sell
36,679
-327
-0.9% -$751 ﹤0.01% 5507
2022
Q4 		$66.6K Sell
37,006
-17,972
-33% -$32.4K ﹤0.01% 5560
2022
Q3 		$93K Sell
54,978
-47,148
-46% -$145K ﹤0.01% 5704
2022
Q2 		$251K Sell
102,126
-78,971
-44% -$184K ﹤0.01% 5519
2022
Q1 		$502K Buy
181,097
+48,941
+37% +$179K ﹤0.01% 5315
2021
Q4 		$704K Buy
132,156
+6,050
+5% +$42.3K ﹤0.01% 5116
2021
Q3 		$1.07M Sell
126,106
-67,356
-35% -$665K ﹤0.01% 4692
2021
Q2 		$2.36M Buy
193,462
+108,934
+129% +$2.15M ﹤0.01% 4046
2021
Q1 		$2.05M Buy
84,528
+12,272
+17% +$331K ﹤0.01% 3959
2020
Q4 		$2.32M Buy
72,256
+64,384
+818% +$2.12M ﹤0.01% 3621
2020
Q3 		$238K Sell
7,872
-9,145
-54% -$278K ﹤0.01% 4847
2020
Q2 		$718K Sell
17,017
-73,020
-81% -$2.69M ﹤0.01% 4167
2020
Q1 		$2.25M Buy
+90,037
New +$2.74M ﹤0.01% 3219

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Goldman Sachs's BDTX Position: Q1 2026 in Review

Goldman Sachs increased its Black Diamond Therapeutics (BDTX) stake by 110% in Q1 2026, buying an estimated $854K and bringing the position to 684,418 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #4806.

Goldman Sachs first reported a position in BDTX in Q1 2020 and has held it in 23 quarters since. The position peaked at $2.36M in Q2 2021. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Goldman Sachs held 684,418 shares of Black Diamond Therapeutics worth $1.46M as of Q1 2026.
  • Goldman Sachs bought 359,091 Black Diamond Therapeutics shares in Q1 2026, an estimated $854K.
  • Black Diamond Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4806 holding.
  • Goldman Sachs first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • Goldman Sachs's Black Diamond Therapeutics position peaked at $2.36M in Q2 2021.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.